Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Workshop attendees training in the labs

Achieving sustainable improvements in health and quality of life for Mexicans requires close collaboration between scientists, technicians, healthcare providers, private initiatives and governments. NDM-Mexico specifically aims to strengthen the networks of collaboration with research universities, hospitals and public health institutes in Mexico.

Our main goal is to support a collaborative hub to facilitate the exchange of exciting new ideas and research activities, to promote the mobility of scientists and students, and to facilitate the sharing of knowledge, experiences, methods, data, protocols, support and guidance. The collaboration also relies on the unparalleled expertise in vaccine research provided The Jenner Institute at the University of Oxford.

This expertise will contribute to the strengthening of research infrastructure in Mexico in an informed manner, and will enable talented Mexican scientists to develop novel vaccines. The collaboration will also allow researchers in Mexico to learn state-of-the-art techniques used to assess cellular immune responses, used on a daily basis in Oxford for clinical and field trials. In addition, Mexican researchers will be able to learn, understand and participate in the process of vaccine development from bench to clinic - a process that is well established in Oxford.

The network includes major research institutions throughout Mexico, with financial support provided by the CONACyT-British Council Newton Fund as well as the generous support from the Nuffield Department of Medicine, the Wellcome Trust, the Oxford Martin School, the UK Medical Research Council, the Liverpool School of Tropical Medicine, the Laboratorio Estatal de Salud Pública de Michoacán (LESP), the Benemérita Universidad Autónoma de Puebla (BUAP), the Universidad Michoacana San Nicolás de Hidalgo (UMSNH) and Universidad Veracruzana (UV). Collaborative funding is earmarked for different purposes, with support for developing the latest vaccine technology and protein production (Oxford University/The Jenner Institute), clinical trial units (Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, IMSS), biosafety level 2 laboratories (Benemérita Universidad Autónoma de Puebla, Laboratorio Estatal de Salud Pública de Michoacán), vector-borne diseases diagnostics (Laboratorio Estatal de Salud Pública de Michoacán), haemostasis expertise (Universidad Michoacana San Nicolás de Hidalgo), sequencing and bioinformatics (Instituto de Biotecnología of the Universidad Nacional Autónoma de México, IBT-UNAM) and virology studies (Escuela Nacional de Ciencias Biológicas of Instituto Politécnico Nacional, ENCB-IPN).